EB 203
Alternative Names: EB-203Latest Information Update: 16 Jul 2024
At a glance
- Originator EyebioKorea
- Class Eye disorder therapies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Age-related macular degeneration
Most Recent Events
- 09 Jul 2024 EyebioKorea plans a phase IIa trial for Age-related macular degeneration in South Korea (Ophthalmic) in July 2024 (NCT06487039)
- 14 Sep 2022 Phase-I clinical trials in Age-related macular degeneration (In volunteers) in South Korea (Ophthalmic) (NCT05538949)